Wednesday, July 8, 2026

Patent intelligence · US

US 10774334

Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

granted A61KA61K2035/11A61K2039/522A61K2039/523
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 8,292
Patent details — US 10774334

Quick answer

US 10774334 (Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety) is held by ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K2035/11, A61K2039/522, A61K2039/523, A61K35/74, A61K39/00

More from ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 10774334?

US 10774334 (Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety) is held by ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10774334?

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 10774334 expire?

Our index shows an expiration date of Sep 10, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.